Live Webinar on the long-term efficacy and safety of anti-CD20 therapies

Anti-CD20 therapies have become a central component in the management of Multiple Sclerosis (MS), with growing evidence supporting their sustained use. In this live webinar, Celia Oreja-Guevara and Patrick Vermersch will review long-term efficacy and safety data, translating current evidence into practical insights for neurologists involved in treatment decisions.

Key Highlights

• Review long-term efficacy data of anti-CD20 therapies in Multiple Sclerosis (MS)
• Assess safety profiles with extended treatment exposure
• Discuss risk–benefit considerations in long-term disease management
• Explore real-world evidence and its implications for clinical practice
• Address monitoring strategies and patient selection over time
• Gain expert perspectives on optimizing treatment decisions

Register to access the webinar

This session will be held live on Zoom. We warmly encourage you to register in advance to secure your place and take part in the exchange of knowledge and discussions.

Language

The session will be held in English with translated auto-captions into many languages, offered by Zoom platform.

This webinar might interest you if you are:

• Neurologists with a particular interest in multiple sclerosis therapies and treatments
• Neurologists in training
• Nurses engaged in the care of patients with multiple sclerosis
• Patient representatives

Questions and discussion

If there are specific questions you would like to see addressed during the session, we encourage you to share them in advance at learning@paradigms.foundation. This will allow the speakers to incorporate them into their presentations.

You will also have the opportunity to raise questions directly and actively contribute to the discussion during the webinar and the dedicated Q&A session.

Technology used

The session will be conducted via Zoom, with access credentials shared upon completion of your registration.

Time and date

The session will be held in English on Wednesday, 29 April 2026 from 5:30 to 6:30 p.m. CET.

Invited Speakers

Celia Oreja-Guevara

Vice Chair of Neurology and Head of Multiple Sclerosis Center at the University Hospital San Carlos, Madrid

After receiving her MD from the University Complutense, Madrid, Professor Oreja-Guevara completed a PhD in neuroimmunology at the Max-Planck-Institute for Neurobiology, University of Munich, Munich (Germany). She then went on to complete a residency in the Department of Neurology at the University of Bochum, Bochum (Germany) and a postdoctoral fellowship in neuroimaging at the University Hospital San Raffaele, Milan (Italy). She has also held posts at the University of Düsseldorf (Germany),Hospital de Fuenlabrada and at the University Hospital La Paz, both in Madrid.

Professor Oreja-Guevara’s research interests centre on family planning, menopause, clinical and neuroimaging correlations in MS and the use of optical coherence tomography. As an investigator, she has participated in a number of MS clinical trials and currently heads Paradigms, an independent and non-profit international group of Multiple Sclerosis experts. Currently, Professor Oreja-Guevara is an expert for the Spanish Medicines Agency and for the Scientific Advisory Group on Neurology of the European Medicines Agency.

Patrick Vermersch

Vice-president of Research in the fields of Life and Health Sciences at the University of Lille

Patrick Vermersch studied medicine at Lille University Hospital (France), where he graduated in Neurology. Between 1990 and 1994 he pursued his training in basic research fields, mainly in cellular biology, obtaining a PhD addressing biochemical abnormalities associated with Alzheimer’s and other neurodegenerative diseases. He also conducted research related to the characterization of post-transcriptional anomalies of tau proteins. His research interests then turned to multiple sclerosis (MS).

Prof. Patrick Vermersch is head of one of the University of Lille’s departments of Neurology which deals with MS and other neuroinflammatory diseases. The department is primarily concerned with neuroimmunology and markers of disease evolution.

Prof. Patrick Vermersch is currently vice-president of research in the fields of Life and Health Sciences at the University of Lille. In 2000, he and colleagues created the first MS network in northern France to improve MS care and research. His current areas of interest are prognostic markers in MS and neuroimmunology in general. He participates in many treatment protocols for MS. He has authored or co-authored approximately 380 scientific papers. His H-index (Web of Science) is 54.

Funding

This webinar is organized with the financial support of Neuraxpharm.

Neuraxpharm has not been involved in the elaboration of the presentations.